Lord, Abbett & Co
CRNX icon

Lord, Abbett & Co’s Crinetics Pharmaceuticals CRNX Stock Holding History

Lord, Abbett & Co’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-724,625
Closed -$37M – 549
2024
Q4 		$37M Sell
724,625
-21,493
-3% -$1.2M 0.12% 219
2024
Q3 		$38.1M Sell
746,118
-141,803
-16% -$7.31M 0.12% 205
2024
Q2 		$39.8M Sell
887,921
-76,647
-8% -$3.54M 0.13% 206
2024
Q1 		$45.2M Buy
964,568
+187,280
+24% +$7.33M 0.15% 192
2023
Q4 		$27.7M Buy
+777,288
New +$23.8M 0.1% 272

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co's CRNX Position: Q1 2025 in Review

Lord, Abbett & Co sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2025, closing a stake of 724,625 shares — an estimated $37M sold.

Lord, Abbett & Co first reported a position in CRNX in Q4 2023 and held it in 5 quarters. The position peaked at $45.2M in Q1 2024. 227 funds tracked by Wall St. Rank hold CRNX as of Q1 2025.

  • Lord, Abbett & Co reported no remaining Crinetics Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 724,625 Crinetics Pharmaceuticals shares in Q1 2025, an estimated $37M.
  • Lord, Abbett & Co first reported a position in Crinetics Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Lord, Abbett & Co's Crinetics Pharmaceuticals position peaked at $45.2M in Q1 2024.
  • 227 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2025.

Based on Lord, Abbett & Co's 13F filing for Q1 2025, filed 13 May 2025.